Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 12/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10820749 | 0.89 | SMN1; SMN2 (0.48) | HDAC3HDAC11HDAC6HDAC1HDAC10 | |
| SCHEMBL85933 | 0.81 | MMP9 (0.43) | HDAC3HDAC11HDAC6HDAC1HDAC10 | |
| SCHEMBL10705064 | 0.81 | HDAC3 (0.42) | HDAC3HDAC11HDAC6HDAC1HDAC10 | |
| SCHEMBL15347243 | 0.78 | HDAC3 (0.38) | HDAC3HDAC11HDAC6HDAC1HDAC10 | |
| SCHEMBL3625069 | 0.76 | CAD (0.43) | HDAC3HDAC11HDAC6HDAC1HDAC10 | |
| SCHEMBL2344195 | 0.76 | CAD (0.43) | HDAC3HDAC11HDAC6HDAC1HDAC10 | |
| SCHEMBL630497 | 0.76 | CAD (0.43) | HDAC3HDAC11HDAC6HDAC1HDAC10 | |
| SCHEMBL2143334 | 0.75 | HDAC3 (0.36) | HDAC3HDAC11HDAC6HDAC1HDAC10 | |
| SCHEMBL14374129 | 0.75 | GLI1 (0.44) | HDAC3HDAC11HDAC6HDAC1HDAC10 | |
| SCHEMBL8426408 | 0.75 | HDAC3 (0.36) | HDAC3HDAC11HDAC6HDAC1HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227498-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 2-cyano(4-ethylphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine | PROBIODRUG AG (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8202897-B2 | pharmaceutically acceptable salt, solvate or polymorph for disease therapy | PROBIODRUG AG (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20110224259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| US-7732162-B2 | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases | PROBIODRUG AG (DE) | 2010-06-08 | — | — | US | disclosed |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2010-05-20 | — | — | US | disclosed |
| US-20080286810-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; drug screening | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080262065-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASES | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080207715-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080200567-A1 | IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS | PROBIODRUG AG (DE) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224259-A1 | NOVEL INHIBITORS | QPCT, GLUL, GLS | HDAC3 1866/4885HDAC11 2762/4885HDAC6 2588/4885 |
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | HDAC3 2015/4885HDAC11 2244/4885HDAC6 2782/4885 |
| US-20080200567-A1 | IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS | QPCT, PCYT1A, PSEN2 | HDAC3 3473/4885HDAC11 2096/4885HDAC6 800/4885 |
| US-20080262065-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASES | GLS, GLS2, GLUL | HDAC3 3307/4885HDAC11 2532/4885HDAC6 2576/4885 |
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | HDAC3 2627/4885HDAC11 2135/4885HDAC6 2281/4885 |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | QPCT, QPCTL, GGCT | HDAC3 3970/4885HDAC11 4062/4885HDAC6 3112/4885 |
| US-20080207715-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | HDAC3 417/4885HDAC11 1638/4885HDAC6 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.